FDA and EMA Evaluate NervGen's Lead Therapeutic Candidate Amid Financial Restatement
What happened
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are currently evaluating NervGen's lead therapeutic candidate. NervGen, a late-stage clinical biopharmaceutical company, focuses on first-in-class neuroreparative therapeutics for spinal cord injury and related neurologic conditions. The company also announced it is expecting to file restated audited financial statements for the year ended December 31, 2025, along with interim filings for the quarter ended June 30, 2026.
From manilatimes.net
Why it matters
The financial restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated deficit. The company stated that these adjustments are non-cash and are not expected to impact its cash reserves, cash runway, or ongoing business operations.
From manilatimes.net
Who's involved
- FDAThe FDA is evaluating the company's candidate.
- European Medicines AgencyThe EMA is evaluating the company's candidate.
Keep exploring
The entities involved
- FDA
-
European Medicines Agency
highest regulatory authority on medicines in the European Union